Related Experiment Video
Updated: Jan 14, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progression
Shuai Yuan1, Dao-Jing Ming1,2, Jiapeng He3
1Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Abstract:
EZH2, a core component of PRC2 complex, silences global gene expression by tri-methylating histone H3K27. It remains an elusive question that EZH2 hyperexpression discords with its H3K27me3 activity of gene suppression in advanced prostate cancer. Here, we report a nascent RNA-dependent PHF19-YTHDC1 condensate capable of switching EZH2-mediated gene suppression to activation during prostate cancer progression. We found that the long isoform of PRC2 accessory subunit PHF19, PHF19L, was highly expressed in advanced prostate cancer that promoted the tumor progression and hormonal therapy resistance. Mechanistically, PHF19L was recruited to the m6A modified nascent RNA through YTHDC1 and formed a liquid-like YTHDC1-PHF19L condensate that pulled the EZH2 away from chromatin, resulting in reduced H3K27me3 deposition and the activated expression of EZH2-repressed genes. Therefore, our study reveals a biomolecular condensate that modulates the switch from EZH2-mediated epigenetic gene silence to activation during the progression of prostate cancer.
Insights
A novel PHF19-YTHDC1 condensate switches EZH2 gene silencing to activation in advanced prostate cancer. This finding reveals a new mechanism driving tumor progression and hormonal therapy resistance.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Research
Background:
- EZH2, a key part of the PRC2 complex, typically silences genes by modifying histone H3K27.
- EZH2's role in gene suppression appears paradoxical in advanced prostate cancer despite its overexpression.
Purpose of the Study:
- To investigate the mechanism behind EZH2's discordant activity in advanced prostate cancer.
- To identify factors that switch EZH2-mediated gene suppression to activation during cancer progression.
Main Methods:
- Analysis of PHF19 long isoform (PHF19L) expression in advanced prostate cancer.
- Investigating the formation of PHF19-YTHDC1 condensates.
- Assessing the impact of these condensates on EZH2 localization and H3K27me3 deposition.
Main Results:
- PHF19L is highly expressed in advanced prostate cancer, promoting tumor progression and therapy resistance.
- A YTHDC1-PHF19L condensate forms on m6A-modified nascent RNA.
- This condensate sequesters EZH2 from chromatin, reducing H3K27me3 and activating repressed genes.
Conclusions:
- A biomolecular condensate involving PHF19L and YTHDC1 switches EZH2 from gene silencing to activation.
- This mechanism contributes to prostate cancer progression and hormonal therapy resistance.
- Reveals a novel epigenetic regulatory mechanism in advanced prostate cancer.
More Related Videos
03:37Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Cell Specific Gene Expression